AASLD ISDA Practice Guideline on treatment of chronic hepatitis B
- PMID: 41186418
- DOI: 10.1097/HEP.0000000000001549
AASLD ISDA Practice Guideline on treatment of chronic hepatitis B
Abstract
Background and aims: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.
Methods: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline.
Conclusions: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
Keywords: antiviral discontinuation; grey zone; hepatocellular carcinoma; horizontal transmission; immune-tolerant; indeterminate; pregnancy; surveillance.
Copyright © 2025 American Association for the Study of Liver Diseases.
References
-
- Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.
-
- Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, et al. Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat. 2017;24:320–329.
-
- Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol. 2022;20:1803–1812 e1805.
-
- Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021;28:1025–1033.
-
- Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81:672–724.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
